REFERENCES
1. Lamarca A, Santos-Laso A, Utpatel K, et al. Group: on behalf of the European Network for the Study of Cholangiocarcinoma (ENS-CCA). Liver metastases of intrahepatic cholangiocarcinoma: implications for an updated staging system. Hepatology 2021;73:2311-25.
2. Committee of Expert Consensus on Pathological Diagnosis of Intrahepatic Cholangiocarcinoma (2022 version). [Expert consensus on pathological diagnosis of intrahepatic cholangiocarcinoma (2022 version)]. Zhonghua Bing Li Xue Za Zhi 2022;51:819-27.
3. Lin J, Zhang H, Yu H, et al. Epidemiological characteristics of primary liver cancer in mainland china from 2003 to 2020: a representative multicenter study. Front Oncol 2022;12:906778.
4. An L, Zheng R, Zhang S, et al. Hepatocellular carcinoma and intrahepatic cholangiocarcinoma incidence between 2006 and 2015 in China: estimates based on data from 188 population-based cancer registries. Hepatobiliary Surg Nutr 2023;12:45-55.
5. Nakanuma Y, Klimstra D, Komuta M and Zen Y. Intrahepatic cholangiocarcinoma. In. WHO classification of tumours. Digestive system tumours. 5th edition. Lyon: IARC Press; 2019. p. 254-259.
6. Zhou HB, Hu JY, Hu HP. Hepatitis B virus infection and intrahepatic cholangiocarcinoma. World J Gastroenterol 2014;20:5721-9.
7. Lei Z, Xia Y, Si A, et al. Antiviral therapy improves survival in patients with HBV infection and intrahepatic cholangiocarcinoma undergoing liver resection. J Hepatol 2018;68:655-62.
8. Wang L, Zhu H, Zhao Y, et al. Comprehensive molecular profiling of intrahepatic cholangiocarcinoma in the Chinese population and therapeutic experience. J Transl Med 2020;18:273.
9. Yamada M, Yamamoto Y, Sugiura T, et al. Comparison of the clinicopathological features in small bile duct and bile ductular type intrahepatic cholangiocarcinoma. Anticancer Res 2019;39:2121-7.
10. Hayashi A, Misumi K, Shibahara J, et al. Distinct clinicopathologic and genetic features of 2 histologic subtypes of intrahepatic cholangiocarcinoma. Am J Surg Pathol 2016;40:1021-30.
11. Vijgen S, Terris B, Rubbia-Brandt L. Pathology of intrahepatic cholangiocarcinoma. Hepatobiliary Surg Nutr 2017;6:22-34.
12. Nguyen Canh H, Takahashi K, Yamamura M, et al. Diversity in cell differentiation, histology, phenotype and vasculature of mass-forming intrahepatic cholangiocarcinomas. Histopathology 2021;79:731-50.
13. Komuta M, Spee B, Vander Borght S, et al. Clinicopathological study on cholangiolocellular carcinoma suggesting hepatic progenitor cell origin. Hepatology 2008;47:1544-56.
14. Yamamoto M, Oshita A, Nishisaka T, Nakahara H, Itamoto T. Synchronous double primary hepatic cancer consisting of hepatocellular carcinoma and cholangiolocellular carcinoma: a case report. J Med Case Rep 2018;12:224.
15. Chen J, He J, Qiu YD. Research advances on cholangiolocellular carcinoma. Chin J Hepatobiliary Surg 2016;22:784-7.
16. Nakanuma Y, Sato Y, Ikeda H, et al. Intrahepatic cholangiocarcinoma with predominant “ductal plate malformation” pattern: a new subtype. Am J Surg Pathol 2012;36:1629-35.
17. Sigel CS, Drill E, Zhou Y, et al. Intrahepatic cholangiocarcinomas have histologically and immunophenotypically distinct small and large duct patterns. Am J Surg Pathol 2018;42:1334-45.
18. Takahashi Y, Sato S, Ishitobi H, et al. Intrahepatic cholangiolocellular and cholangiocellular carcinoma - differences in the 18F-FDG PET/CT Findings. Intern Med 2017;56:3027-31.
19. Sheng X, Ji Y, Ren GP, et al. Liver Cancer Pathology Group of China (LCPGC). A standardized pathological proposal for evaluating microvascular invasion of hepatocellular carcinoma: a multicenter study by LCPGC. Hepatol Int 2020;14:1034-47.
